A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...